South Korea
· Delayed Price · Currency is KRW EyeGene Statistics
Total Valuation
EyeGene has a market cap or net worth of KRW 72.30 billion. The enterprise value is 41.65 billion.
| Market Cap | 72.30B |
| Enterprise Value | 41.65B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EyeGene has 27.03 million shares outstanding. The number of shares has decreased by -0.34% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 27.03M |
| Shares Change (YoY) | -0.34% |
| Shares Change (QoQ) | +186.51% |
| Owned by Insiders (%) | 6.59% |
| Owned by Institutions (%) | 0.10% |
| Float | 19.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.58 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.96 |
| EV / Sales | 12.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.62 |
Financial Position
The company has a current ratio of 5.55, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.55 |
| Quick Ratio | 5.39 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -31.60 |
Financial Efficiency
Return on equity (ROE) is -28.19% and return on invested capital (ROIC) is -15.64%.
| Return on Equity (ROE) | -28.19% |
| Return on Assets (ROA) | -13.26% |
| Return on Capital (ROIC) | -15.64% |
| Revenue Per Employee | 79.46M |
| Profits Per Employee | -343.70M |
| Employee Count | 41 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 3.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -30.62% |
| 50-Day Moving Average | 2,861.20 |
| 200-Day Moving Average | 3,074.10 |
| Relative Strength Index (RSI) | 39.19 |
| Average Volume (20 Days) | 49,588 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EyeGene had revenue of KRW 3.26 billion and -14.09 billion in losses. Loss per share was -658.25.
| Revenue | 3.26B |
| Gross Profit | 1.68B |
| Operating Income | -14.62B |
| Pretax Income | -15.23B |
| Net Income | -14.09B |
| EBITDA | -12.26B |
| EBIT | -14.62B |
| Loss Per Share | -658.25 |
Balance Sheet
The company has 34.87 billion in cash and 3.94 billion in debt, giving a net cash position of 30.92 billion or 1,144.05 per share.
| Cash & Cash Equivalents | 34.87B |
| Total Debt | 3.94B |
| Net Cash | 30.92B |
| Net Cash Per Share | 1,144.05 |
| Equity (Book Value) | 53.40B |
| Book Value Per Share | 1,965.69 |
| Working Capital | 30.30B |
Cash Flow
In the last 12 months, operating cash flow was -19.30 billion and capital expenditures 3.37 billion, giving a free cash flow of -15.93 billion.
| Operating Cash Flow | -19.30B |
| Capital Expenditures | 3.37B |
| Free Cash Flow | -15.93B |
| FCF Per Share | -589.25 |
Margins
| Gross Margin | 51.43% |
| Operating Margin | -448.69% |
| Pretax Margin | -467.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EyeGene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.34% |
| Shareholder Yield | 0.34% |
| Earnings Yield | -24.61% |
| FCF Yield | -22.03% |
Stock Splits
The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 28, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
EyeGene has an Altman Z-Score of 0.01. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.01 |
| Piotroski F-Score | n/a |